RFA-DC-25-003: Cooperative Agreement for In Vivo High-Resolution Inner Ear Imaging (U01, Clinical Trial Required)

RFA-DC-25-003: Cooperative Agreement for In Vivo High-Resolution Inner Ear Visualization (U01 Clinical Trial Required)

NIDCD’s RFA-DC-25-003 is a specialized federal biomedical funding opportunity for teams building the next generation of non-invasive inner-ear imaging technologies. It is not a discovery-only grant for routine observational studies. It is a clinical-trial-centered cooperative agreement, and the announcement explicitly narrows scope to higher-risk projects that require stronger oversight and translational intent.

For teams working on hearing, balance, or communication disorders, this NOFO is unusual in one important way: the program goal is squarely at the interface between device/technology development and clinical outcomes. It asks whether your project can push imaging from a lab or early-use phase into clinically meaningful use, and whether the trial design itself is coherent enough for eventual human impact. In practice, this makes it less like a short pilot and more like a structured path toward clinical maturity.

What this opportunity is and what it is not

This opportunity is officially titled Cooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (U01 Clinical Trial Required). It is reissued from earlier RFA-DC-24-005 and is administered by NIH through the National Institute on Deafness and Other Communication Disorders (NIDCD).

What it supports:

• investigator-initiated high-risk clinical trials aimed at in vivo structural and functional imaging in the living human inner ear;
• new imaging modalities, or substantial improvement of existing modalities, to improve spatial and functional resolution;
• imaging probes/contrast agents that can improve localization or diagnostic utility;
• translation pathways into clinical settings, not purely bench-only proof-of-concept work.

What it does not support:

• non-clinical trials that do not satisfy the U01 criteria;
• low-risk studies that should be considered under the companion RFA-DC-25-005 (R01 clinical-trial optional);
• proposals that are not aligned to NIDCD mission areas.

The NOFO points to a broad technical vision: high-resolution structural and functional imaging that materially improves our ability to visualize auditory and vestibular pathology in ways that can alter diagnosis, treatment planning, and care pathways.

Key opportunity details at a glance

Why teams pursue this call

This call is best for teams that can explain how a technical imaging advance changes real clinical behavior. It is not enough to demonstrate novelty; proposals are expected to show a development-to-translation arc.

Typical applicants that do well include:

• translational imaging scientists with established partnerships in otology, neuroradiology, and clinical trial infrastructure;
• interdisciplinary groups linking imaging physics, data science, signal processing, and ear-specific clinical endpoints;
• teams already thinking about regulatory readiness, data governance, and study operations in clinical environments.

Why this is a strong strategic call:

1. It bridges technology development with an NIH-defined clinical trial standard.
2. It opens a path for high-risk ideas that need institutional oversight and staged validation.
3. It gives reviewers a clear lens: feasibility + rigor + path to clinical usefulness.
4. It is not narrowly local or regional; the eligibility set is broad enough for domestic and foreign institutions, with explicit provisions for non-U.S. collaborators.

Who is eligible

The NOFO is broad on organizational type. It allows applications from:

• public and private higher-education institutions;
• nonprofits (with and without 501(c)(3) status);
• for-profit entities and small businesses;
• local and state governments, federal entities and territories;
• faith-based/community organizations and regional entities;
• non-domestic entities (foreign organizations), plus foreign components of U.S. organizations.

A few constraints matter:

• It is a required-clinical-trial opportunity. If your proposal is not a clinical trial, it will not be eligible here.
• The trial has to meet at least one high-risk criterion: need for FDA oversight (IND/IDE), higher-risk design features, or a phase III-style efficacy objective.
• At least one noncompliant element is likely fatal: proposing more than one clinical trial, or providing no clear milestone/contingency plan, or not including the required five research strategy points.

For NIH systems compliance, applicants must complete and maintain required registrations before submission:

• SAM registration (with renewal expectations), including required entity identifiers;
• eRA Commons;
• Grants.gov profile and linked access.

The application system expects registrations complete in time—late or incomplete registrations are not valid delay reasons.

Practical eligibility check for your team

Before drafting, validate this list:

1. Do you have an intervention pathway that qualifies as a U01-level trial?

   • FDA-relevant intervention, higher-risk method, or Phase III-style design?

2. Can you justify one clinical trial only per application?

   • The NOFO explicitly rejects proposals proposing more than one clinical trial.

3. Do you have a realistic translation plan?

   • The program is not for purely technical papers. You need a route from method development to clinical setting, with use-case and operational implications.

4. Do your institutional registrations work months in advance?

   • Expect at least several weeks for SAM/eRA/Commons readiness.

5. Can your data-sharing and trial governance materials meet requirements?

   • Resource-sharing plans, data management plans, and subject-protection documentation are not optional extras.

If several answers are weak, this is likely not the first choice call for your concept until those elements are strengthened.

Application process and required materials

NIH NOFOs are explicit about process. For this one, the preferred preparation method is to access the package through ASSIST, Grants.gov Workspace, or an institutional system-to-system solution. In practical terms, your immediate prep has to run on two tracks in parallel:

1. Submission architecture track

   • eRA Commons account setup for PD/PI and org representative.
   • SAM.gov readiness, including registrations and identifiers.
   • Internal administrative sign-off on roles and PI account mapping.

2. Content track

   • SF424/R&R forms completed per base NIH instructions and NOFO supplements.
   • PHS 398 Supplement with expanded research strategy.
   • Human subjects/trial details with proper forms and population details.
   • Data management and sharing narrative.
   • Appendices only per allowed limits.

The NOFO’s five required research strategy points are central. At minimum, your narrative must include:

• the specific imaging dimension(s) improved (spatial/temporal/functional);
• measurable resolution gains and their clinical relevance;
• translation timeline into awake-human clinical settings where relevant;
• intended clinical use scenarios and decision-support impact;
• target inner-ear pathologies and treatment consequences.

For clinical trials, reviewer quality is mostly driven by whether the plan is coherent enough to be executed. NIH expects milestone architecture, operational governance, and contingency responses. A strong application should describe how risks are tracked, how subject protection is handled, how data quality is maintained, and what happens if recruitment lags.

Timeline and how to read the deadlines

This opportunity has multiple due dates. The current listed key dates include:

• June 3, 2026 (new/renewal/resubmission)
• October 1, 2026
• October 1, 2027

All dates listed are 5 PM local org time. The NOFO indicates that applications are closed to late submissions and explicitly encourages early submission.

A practical planning timeline:

• Month 1–2: finalize mechanism fit and determine if your study genuinely meets U01 criteria.
• Month 2–3: lock trial hypothesis, endpoints, and inclusion logic; pre-register operational assumptions.
• Month 3–4: finalize PI roles, institutional agreements, and mandatory registrations.
• Month 4–5: draft PHS 398 materials, Data Management, human subjects, and trial records.
• Month 5: internal mock-submission, compliance audit, and final submission.

Because this is a clinical trial pathway, don’t underestimate internal compliance review time. Teams that skip this underestimate lead to either late submissions or withdrawn technical sections.

Common mistakes that lose applications early

1. Submitting as low-risk work under U01. The NOFO has an explicit partition: low-risk work should go to RFA-DC-25-005 in the companion stream. If your design does not clearly justify the U01 rationale, it is vulnerable.

2. Multiple trial concepts in one proposal. The rules require one clinical trial per application.

3. No milestone and contingency design. For this call, this is a major non-response risk. Reviewers expect operational robustness.

4. Underestimating regulatory preparation. Missing FDA pathway thinking, inadequate clinical infrastructure, or unclear IRB or safety governance is typically judged as feasibility risk.

5. Ignoring required five research strategy prompts. These prompts are not cosmetic. They are directly tied to responsiveness.

6. Not complying with registration lead times. SAM/eRA/Grants.gov misalignment is one of the most common pre-review failures.

7. Treating this as an R01-style exploratory grant. Reviewers and program staff evaluate this as a structured cooperative agreement with active NIH involvement and strong execution demands.

Review expectations, scoring logic, and what reviewers like

The peer review path is standard NIH two-step review, but with high practical emphasis on trial quality. Reviewers evaluate scientific merit while simultaneously checking whether the proposal is implementable within timeline and budget.

Strong proposals usually stand out in four ways:

• Mechanistic and translational clarity: why this imaging technology is needed and where it changes diagnosis, management, or treatment.
• Trial-level discipline: milestone sequencing, contingency actions, and realistic enrollment and timeline logic.
• Measurement strategy: how data quality, imaging endpoints, and outcome validity are protected.
• Institutional readiness: teams that can demonstrate execution capability (not just technical brilliance) consistently score higher.

Common “good but losing” applications have deep technology but weak human pathway reasoning. The call is intentionally clinical: technical merit must be tightly coupled to clinical implementation.

Preparation roadmap you can run

Use this as a practical sequence:

Step 1: Decide if your study belongs to U01 or companion R01

Check your intervention risk profile honestly. If you do not require FDA oversight, high-risk rationale, or efficacy-oriented phase III logic, do not force U01. RFA-DC-25-005 exists for this reason.

Step 2: Build the trial architecture first

Draft a short trial operations map before writing background sections:

• study population and recruitment source,
• imaging endpoint and endpoint validity,
• safety and monitoring chain,
• pre-implementation docs plan (IRB approvals, DSMB logic as relevant, case report framework, intervention procurement, SOPs).

Step 3: Translate technical claims into measurable gains

For each imaging promise, define the quantitative gain target and its clinical interpretation. A claim like “better resolution” must become “X-fold gain in practical diagnostic utility for Y pathology.”

Step 4: Lock governance and compliance dependencies

Map who has administrative role in SAM/eRA/Grants.gov, and ensure PI account readiness. NIH’s NIH-assistive systems are not forgiving if account setup and institutional signatures are missing on submission day.

Step 5: Run a responsiveness pass

Use a checklist against the NOFO’s explicit response criteria:

• one clinical trial only,
• mission alignment,
• required strategy points,
• budget cap and justification,
• registration completeness,
• no prohibited application types.

Step 6: Write for reviewer workload

A strong reviewer can quickly tell whether your team knows the field and the clinical process. Use crisp sectioning. Show direct evidence of translational viability rather than listing disconnected aims.

FAQ

Is this only for U.S. institutions?

No. The NOFO explicitly allows non-domestic entities and foreign components in U.S. organizations. This is still a U.S.-administered NIH opportunity, so U.S. federal systems and eligibility mechanics still apply.

Is there a single deadline?

No. The announcement lists multiple submission cycles. Treat it as a rolling opportunity with specified due dates, including 2026 and 2027 cycle dates.

Can small businesses apply?

Yes, small businesses are listed among eligible organization types.

Does this require cost sharing?

No, the NOFO explicitly states cost sharing is not required.

What is the funding amount?

The text states NIDCD intent of approximately $2 million in both FY 2026 and FY 2027 (shared with the companion announcement), with less than $500,000 direct costs per year per award unless prior approval is obtained.

Can applicants include publications in appendices?

Only limited appendix materials are allowed. Publications are generally disallowed except narrow exclusions like blank questionnaires/surveys.

What happens after submission

If the application passes peer review, funding decisions then factor in peer review, available funds, and program priorities. Even strong science is not enough if the proposal is out of compliance or cannot pass initial administrative checks.

Typical compliance checkpoints include:

• successful eRA submission validation,
• institutional and PI registration verification,
• alignment with trial definitions and section requirements,
• potential federal checks against applicant responsibility records.

For an investigator considering a high-stakes application calendar, the key recommendation is to prioritize administrative readiness and trial operations design before polish of narrative prose.

Final fit assessment

If your group already has a defined clinical imaging protocol and can demonstrate operational capacity for a high-risk clinical trial, RFA-DC-25-003 is a targeted, high-leverage option. If you still have a technology concept without trial readiness, this NOFO will quickly expose execution gaps.

The practical bar is not simply novelty. It is “Can this project become a clinical process, on schedule, with auditable rigor, and with coherent management?” That framing should guide every section of your submission.

Official links

• Official NOFO page: https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-25-003.html
• Companion announcement reference (R01, clinical-trial-optional): https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-25-005.html
• NIDCD research page context: https://www.nidcd.nih.gov
• NIH portal and grant administration references linked from the NOFO: NIH ASSIST, eRA Commons, Grants.gov